vTv Therapeutics (NASDAQ:VTVT) Stock Passes Below Fifty Day Moving Average - Time to Sell?

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $37.10 and traded as low as $34.13. vTv Therapeutics shares last traded at $34.85, with a volume of 88,495 shares traded.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Roth Mkm started coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They issued a "buy" rating and a $58.00 target price for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of vTv Therapeutics in a research note on Friday, March 27th. BTIG Research reiterated a "buy" rating and issued a $49.00 price objective on shares of vTv Therapeutics in a report on Wednesday, March 11th. Wall Street Zen upgraded shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Finally, TD Cowen assumed coverage on shares of vTv Therapeutics in a report on Monday, January 5th. They set a "buy" rating on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $53.00.

vTv Therapeutics Stock Down 13.8%

The stock has a 50 day moving average of $37.10 and a 200 day moving average of $32.97. The company has a market capitalization of $137.31 million, a price-to-earnings ratio of -10.40 and a beta of 0.40.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.51. As a group, sell-side analysts anticipate that vTv Therapeutics Inc. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Several large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the fourth quarter worth $221,000. 683 Capital Management LLC acquired a new stake in vTv Therapeutics during the 4th quarter worth about $731,000. Geode Capital Management LLC grew its holdings in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP raised its position in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company's stock worth $3,463,000 after acquiring an additional 51,000 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.